Clinical Effectiveness of TARA Compared to Standard Treatment for Adolescents and Young Adults With Depression

Summary

Participation Requirements

Description

The primary aim of this study is to investigate the clinical effectiveness of TARA in treating depression in adolescents and young adults by using a Randomized Controlled Trial (RCT)-design, with an active control group based on standard treatment (ST) for depression in Child and Adolescent Psychiat...

The primary aim of this study is to investigate the clinical effectiveness of TARA in treating depression in adolescents and young adults by using a Randomized Controlled Trial (RCT)-design, with an active control group based on standard treatment (ST) for depression in Child and Adolescent Psychiatry (CAP) and Youth Clinics (YC). Secondary aims are: 1. to identify potential mediating effects of improved emotion regulation, sleep and psychological flexibility on the treatment effect of TARA, 2. Investigate the effects the two treatment-arms on bioindicators for depression, 3. Increase the understanding of the subjective experience of depression onset and to what extent the treatments addressed what is perceived to drive the onset and maintenance of depression. The study is designed as a partially nested multicenter parallel-group RCT with two treatment arms: 1) TARA and 2) ST, including but not limited to anti-depressive medication such as selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy. Participants are randomized to one of the two treatment arms, both delivered via the local CAP and YC unit where the participants are being either referred to, are wait-listed or treated. The study is planned in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and will be analyzed and reported in accordance with the recommendations in consolidated standards of reporting trials (CONSORT). Participants and procedures Recruitment, treatment and data collection will be conducted in three cities in Northern Sweden, each with 1-2 centers. Several centers will be included step-wise in the RCT, until a sufficient recruitment capacity has been reached. Before including a new center the implementation of Good Clinical Practice-guide-lines, a clinical research infrastructure and the training of study-staff must be satisfactory and a pilot trial will have been conducted at each site to show feasibility. The investigators intend to recruit participants from the Child- and adolescent psychiatry (CAP) specialized outpatient academic unit and the youth outpatient community clinic (YC) in the university city Umeå (population 89 000), CAP and YC in Skellefteå (population 36 000) and CAP in Örnsköldsvik (population 33 000). The CAP unit in Sundsvall (population 55 000) is also prepared for participation, this center will be activated only if needed to maintain recruitment pace. Depending on the general recruitment rate and the feasibility of implementation of the study protocol at the different sites, one or several of the sites may be omitted. Adolescents and young adults (15-22 years of age) with depression will be recruited to the RCT. In this study depression is defined as having a diagnosis of major depressive disorder (MDD) or persistent depressive disorder (PDD) according to DSM 5 (dysthymia in DSM-IV) or a clinician depression rating >40 using Children's Depression Rating Scale - Revised (CDRS-R). The recruitment is done through three possible pathways: 1) at the time of an incoming referral, 2) by clinical staff who recruit potential participants at their first clinical visit, from those wait-listed for treatment, or during ongoing standard treatment and 3) by participants responding to flyers posted in the local waiting-rooms and at the student health clinic at the University of Umeå. Those who show interest in participating in the study after having received introductory information, will be provided more detailed information over the phone. At that time initial assessment for eligibility will also be performed. Further eligibility-screening is then performed online and in person (see inclusion and exclusion criteria). The decision to include a participant in the study will be made by a study-clinician on the basis of the eligibility criteria and the final decision in case of uncertainty will be made by the PI. Before final inclusion, participants will provide written informed consent. In addition, parents/legal guardians will provide written informed consent for participants that are <18 years old. Study participation is voluntary and can be cancelled by the participant at any time. Participants randomized to TARA who are taking antidepressant medication with maintained depressive symptoms will be offered support from a child psychiatrist to discontinue their medication over a period of 2-4 weeks and start TARA as a stand-alone treatment. Those who prefer to continue their antidepressant medication and those who require more extensive tapering regimens will still be included in the study, enter treatment as allocated and be analyzed according to the intention to treat design. All ST will take place at the local CAP and YC units and/or be delivered online. Any worsening of symptoms during the ST will be handled by the clinic according to their standard procedures. TARA will be delivered as an online group-intervention and routines for handling potential increase of depression symptoms during TARA are explained in detail in the study protocol. Assessment procedure At baseline, before inclusion, self-report of sociodemographic background, social support, dissociative symptoms and adverse childhood events is completed. After inclusion and before randomization (T0), at 3 months (T1), at 6 months (T2) and at 2 years (T3) from T0 additional self-report questionnaires are completed, for details see outcome measures. Clinician rating of depression symptom severity and global level of functioning is conducted at T0 and T1. Blood and hair samples are collected and heart rate variability (HRV) is measured at T0 and T1. For a subgroup of randomly selected participants from both study arms in the Umeå YC/CAP-populations a 2-3 weeks of accelerometry will also be carried out at T0, 6 weeks into the study (T0,5) and at T1. MRI data acquisition will be performed at T0 and T1 in approximately n=22 randomly selected participants from each study arm from the Umeå YC/CAP-populations. MRI data acquisition will not start at the beginning of the study but will be initiated at a later time. The TARA-participants will provide brief self-assessment and session-evaluation at the beginning and end of each session. Additionally, to evaluate mediation effects of emotion regulation, sleep and psychological flexibility three self-report scales will be administered halfway through the TARA-treatment. Participants who do not show up for data collection will be reminded by the research team through email and/or telephone contact. Randomization When 6 eligible participants have been recruited at a study-site, these participants will all undergo T0 assessments within a period of 2 weeks. Next, the participants will be randomized as a group to one of the two study arms in a 1:1 allocation ratio, by a computer-generated allocation sequence using permuted blocks and stratification for center. Block sizes will vary randomly between 2 and 4 and the first value on the randomization list at each center will be discarded at random with 50% probability to reduce the risk of breaking the allocation concealment. Randomization will continue until n=67 has been reached in each arm. Codes will be used to increase information confidentiality and participant anonymity. Treatment allocation will be performed on the basis of these codes, by a different team at the Umeå University clinical research center (CRC). The CRC will not release the randomization results until the participants have been recruited into the trial and all baseline and T0 assessments have been completed. The process will thus be separate from the patient enrolment process at the clinics. Participants, TARA-facilitators and standard treatment personnel cannot be blind to treatment allocation, but clinical outcome-assessors and statistical analysts will be blinded. Analysis Data from the pilot-groups at each site will be analyzed and presented separately. For the RCT, the analyses will be performed after the last participant is out and data collection at T2 is complete. No interim analyses will be conducted. Descriptive statistics will be reported using standard measures and the baseline characteristics of the included participants will be reported per randomization group in a baseline table. All randomized participants will be included in the main analysis that will be performed according to intention to treat. The primary outcome RADS-2 total raw-score at 3 months follow up (T1) aims to investigate the differences between the two treatment arms in reduction of depressive symptoms and will be analyzed using mixed effects modelling to account for the clustering caused by partial nesting. The main mixed effects model will include fixed effects for treatment allocation, RADS-2-score at T0, age-group (dichotomous, 15-17 and 18-22 years old), study site and sex. The clustering effect will be modelled using a random intercept for each intervention group. Superiority will be concluded if 95% confidence intervals are not overlapping between the two study-arms. Additionally, a non-inferiority margin is defined as a RADS-2 total raw-score difference of 8 points. The investigators consider this to be the maximal clinically acceptable difference in light of the other potential benefits of TARA. If superiority is not demonstrated, additional specific equivalence- and non-inferiority analyses will be performed. Since participants who withdraw or drop out may tend to have a lack of response, using the full analysis set is likely to be biased toward demonstrating non-inferiority. Therefore, a per-protocol population (defined in the study protocol) will be used in this analysis. Additionally, to avoid making biased conclusions based on the per-protocol population the analysis will also be performed on the intention to treat population and non-inferiority will be concluded if the analyses reach similar results. Participants who do not show up for T0 assessment will not be randomized and will be considered external dropouts. Participants who complete T0-assessment and drop out before randomization will also be considered external dropouts. Participants who are randomized but do not show up for treatment or show up but do not complete the allocated treatment will be considered internal dropouts and will be included in the analysis. All participants lost to follow-up will be contacted and asked about the reason for the drop-out. This will enable a comparison between the study arms regarding the reasons for drop-out and an examination of potential sources of bias in attrition. Additional sensitivity analyses will be performed on the primary outcome to test the robustness of findings. Secondary outcome variables will be analyzed by using similar mixed effects models as for the primary outcome, and adjusting for the T0-value for each respective outcome. Time-point (T0, T1, T2) and the allocation by time interaction will be included as fixed effects in these models. Time plan The investigators are currently piloting TARA at some of the study sites and expect to begin recruitment for the RCT in February 2021. The final data collection at T2 is estimated to be completed in 2025.

Tracking Information